Company Overview
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -99.83% |
| 6 Months: | -99.64% |
| 3 Months: | -92.04% |
| 1 Month: | -81.96% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)20.25 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 100.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 20 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CDT CDT Equity Inc. PHARMA | 0.62 | -0.00 | $8.49M | 0.00% | - | -69.68% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -4.38K | -263.72K | -279.42K | -933.00K | -1.51M | -1.31M | -430.00K | -2.96M | -3.14M | -5.81M | -3.62M | -4.95M | -7.03M | -3.66M |
| Net Income | -4.38K | -253.54K | -117.54K | -956.00K | -1.67M | -2.11M | 2.62M | -3.55M | -5.38M | -6.46M | -4.75M | -6.03M | -7.12M | -4.06M |
| Diluted EPS | - | - | - | -0.03 | -0.03 | -0.03 | 0.01 | -4.81 | -109.33 | -889.58 | -3,670.27 | -5.46 | -13.16 | -5.56 |
| R&D Expense | - | - | - | 38.00K | - | - | - | 128.00K | 25.00K | 3.09M | 916.00K | 1.86M | 1.53M | 778.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Income | -3.16M | -5.26M | -15.42M | -36.76M |
| Net Income | -4.89M | -535.00K | -17.80M | -39.22M |
| Diluted EPS | -0.13 | -8.92 | -61,598.62 | -1,177.89 |
| R&D Expense | 37.00K | 90.00K | 3.38M | 5.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | 213.12K | 5.00K | 506.00K | 900.00K | 7.22M | 4.19M | 5.65M |
| Total Equity | -5.96M | -10.09M | -12.02M | -14.51M | -457.00K | -6.79M | -7.17M |
| Cash & Equivalents | 48.55K | 345.78K | - | - | 4.23M | 554.00K | 1.51M |
| Total Liabilities | 192.51K | 10.09M | - | - | 7.68M | 10.99M | 12.82M |
| Current Liabilities | 192.51K | 4.18M | - | - | 1.80M | 10.74M | 12.82M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -2.27M | -7.72M | -9.68M | -15.55M |
| Investing Cash Flow | -183.00K | 725.00K | -43.00K | -808.00K |
| Financing Cash Flow | 2.45M | 10.93M | 6.07M | 17.42M |
| Capital Expenditure | - | - | -51.00K | - |
| Free Cash Flow | - | - | -9.73M | - |
| Share Buybacks | - | - | - | 106.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 48.4% | 117.1% | 262.1% | 547.1% |
| ROCE % | 75.8% | -97.0% | 235.5% | 512.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 0.04% | 6.12K | $1.06K |
| 2 | Virtu Financial LLC | 0.02% | 2.72K | $473 |
| 3 | Citadel Advisors Llc | 0.02% | 3.23K | $562 |
| 4 | Financial Management Professionals, Inc. | 0.01% | 1.00K | $174 |
| 5 | Tower Research Capital LLC (TRC) | 0.01% | 910 | $158 |
| 6 | Geode Capital Management, LLC | 0.01% | 1.67K | $291 |
| 7 | Xtx Topco Ltd | 0.01% | 1.29K | $224 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CDT
$CDT stock is down 37% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOU0hTV25ZVTQ2bEdZOXczb0VuUThFQkpDZEhrckZ2clhuYjk0cy1zNnF0d1dBZlI5MUlvWmNURm9mS0R0SnBzYmJBdFRrWDZBMTJ2NXpIRFQwX09RTTBMRUJFY0tDd1VzOW1TVHlJMWMxNFNhREVmLUZrNklJaGdDLTcxcm9ORGVDMWxMeX…
[Form 4] CDT Equity Inc. Insider Trading Activity - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOOHh6M0RsZFlyTXlEeFh6S01VVXgtYk9PSzBIY1prc0VTNDY3b3hPLXBHQ1F5Y3J1RXF6RnpiaEdVUW1ERWVkWk5keW1kS2FXaXNPT2RKNDVnV3JuaXpRcHVhZWRobXFXMExnT1RjUjZUX0daUTc5Z09sRGpkZWdXNzVlaDhwUDZxbVFJbk…
CDT Equity Amends $8 Million Sarborg Investment and Adds $542K Convertible Note, Later Repaid - tradingview.com
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPSU41cnZDLVpnOVpTSi11a0I3VXB6ZklMS0FmUVl2eVRRWnN0RXdTblVRV0R0eWtFNF8zUTBwb19RSlNFbEwwR1ZRN0FIZ0VBTzJreE1FZ1N1dEY2WmF2X1NVUzhXZnpiU1RvaGtaVnh4dEthWnJIM3VnRTAwNXhxb05ZenJfYlIyQWc0el…
CDT Equity Share Issuance Boosts Nasdaq Compliance Status - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPa0RnUnZNY3FraWFIeGpNRGVrTGZYelc5SFBURlhHbUlvLWhZN0NhaUo4M25CT0tjRWJLWHFkOWVCNlBkUFVoeFpxSjI1eDVwM294N2lZVTBTN2hndnJiT1p1dlBhU0JTd0tILUdYZm5Za2tjdlRhRUxMNWNJN2NRVkdfOGhGbnBPODBsdD…
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies - WBOC TV
<a href="https://news.google.com/rss/articles/CBMi-AFBVV95cUxObDlqWFIzT2I4cUJILU04bXJ6MzZLdzJaRkl5T25FUzRKaldacDBCcXNyQllIZmFQNDJOb01keGZQS3ZHdTE1WFBvbmltZWc4ZkpwSkw4MS1nTHhMc0l0dkFZUmJxdUtEOEYtZDBaMXFVMUhWdzZTQ0ZRRk4ySG9aS1BHU1ZvTlk5V0lQMG…
These stocks are moving in today's after hours session - ChartMill
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVHdPd2htcl9NQUN3OXEyRTF6UVlkY242Wms2YXBJN05DU2N6V191VkZxNENZR2Vwdnd2UWl1SVpvQ2diTk81WUdGYVZPeDBEajgtZmJRN3d3SWhTUndRN0dIZUxTSWJsUkNYVEFyekE0ZURDRzk2SEpPTFpYVlgzZmFiRmRScXVTUHRjcF…
CDT — Frequently Asked Questions
What is the current share price of CDT Equity Inc. (CDT)?
As of 2026-09-19 21:16 PDT, CDT Equity Inc. (CDT) trades at $0.62 on NasdaqCM. Its 52-week range is $0.62 to $2,360.00.
What is the market capitalisation of CDT?
CDT Equity Inc. (CDT) has a market capitalisation of $8.49M on NasdaqCM.
What is the return on equity (ROE) of CDT?
CDT has a return on equity (ROE) of -69.68%.
Is CDT a good stock to buy?
This page provides a data-driven analysis of CDT Equity Inc. (CDT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.